Research Corporation Technologies Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
7
- Investments
-
93
- Portfolio
-
25
- Exits
-
39
Research Corporation Technologies General Information
Company Description
Founded in 1987, Research Corporation Technologies is a venture capital firm based in Tucson, Arizona. The firm seeks to invest in technology companies operating in the medical device, therapeutic, and biotechnology sectors.
Business Details
Website
rctech.comYear Founded
Investor Status
Trade Association
Primary Investor Type
Other Investor Types
Corporate Office
- 6440 North Swan Road
- Suite 200
- Tucson, AZ 85718
- United States
Research Corporation Technologies Investments (93)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Pheon Therapeutics | 21-May-2024 | Later Stage VC | Drug Discovery | Clinical Trials - Phase 1 | ||
Q'Apel Medical | 09-May-2024 | Therapeutic Devices | Generating Revenue | |||
Pheon Therapeutics | 04-Mar-2024 | Drug Discovery | Clinical Trials - Phase 1 | |||
S2 Genomics | 23-Jan-2024 | Other Devices and Supplies | Generating Revenue | |||
iotaMotion | 13-Apr-2023 | Surgical Devices | Generating Revenue | |||
Biolog | 06-Feb-2023 | Biotechnology | Generating Revenue | |||
Halo Labs | 29-Dec-2022 | Discovery Tools (Healthcare) | Generating Revenue | |||
Flagship Biosciences | 31-Aug-2022 | Discovery Tools (Healthcare) | Generating Revenue | |||
Kemp Proteins | 21-Jun-2022 | PE Growth/Expansion | BPO/Outsource Services | Profitable | ||
seqWell | 29-Mar-2022 | Later Stage VC | Medical Supplies | Generating Revenue |
Research Corporation Technologies Exits (39)
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
Esperance Pharmaceuticals | 19-Nov-2024 | Out of Business | |
Curonix | 29-Oct-2022 | ||
EnCompass Technologies (Energy Marketing) | 02-Aug-2022 | ||
Tonbo Biosciences | 02-Nov-2021 | ||
Distributed Bio | 31-Dec-2020 | ||
Orflo Technologies | 11-Nov-2019 | ||
Gold Standard Diagnostics | 06-Jul-2018 | ||
OncoGenex Pharmaceuticals | 01-Aug-2017 | ||
Catheter Connections | 31-Jan-2017 | Merger/Acquisition | |
Rubicon Genomics | 17-Jan-2017 | Merger/Acquisition |
Research Corporation Technologies Investments by Industry, Year, and Region
Research Corporation Technologies Co-Investors (25)
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
BroadOak Capital Partners | 6 | ||||
Agilent Technologies | |||||
Ampersand (Private Equity) | |||||
Atlas Venture | |||||
Forbion |
Research Corporation Technologies FAQs
-
What is Research Corporation Technologies?
Founded in 1987, Research Corporation Technologies is a venture capital firm based in Tucson, Arizona.
-
When was Research Corporation Technologies founded?
Research Corporation Technologies was founded in 1987.
-
Where is Research Corporation Technologies headquartered?
Research Corporation Technologies is headquartered in Tucson, AZ.
-
What is Research Corporation Technologies's total asset value?
Research Corporation Technologies has around
in total assets under management. -
How many investments has Research Corporation Technologies made?
Research Corporation Technologies has made 93 investments.
-
What has Research Corporation Technologies invested in?
Research Corporation Technologies has made numerous investments in companies like Pheon Therapeutics, Q'Apel Medical, and S2 Genomics within the Drug Discovery, Therapeutic Devices, and Devices and Supplies industries.
-
What has Research Corporation Technologies invested in recently?
Research Corporation Technologies's latest investment was on 21-May-2024 in Pheon Therapeutics, a company within the Drug Discovery industry.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »